What non‑controlled medications are recommended for insomnia in an adult without severe psychiatric illness, substance use disorder, or significant hepatic or renal impairment?

Non-Controlled Medications for Insomnia in Adults

For adults with chronic insomnia, the strongest evidence supports using low-dose doxepin (3–6 mg) for sleep-maintenance problems, ramelteon (8 mg) for sleep-onset difficulty, or suvorexant (10–20 mg) for sleep maintenance, while explicitly avoiding trazodone, diphenhydramine, and melatonin despite their widespread off-label use. 1, 2

First-Line Non-Controlled Options by Sleep Pattern

For Sleep-Onset Insomnia (Difficulty Falling Asleep)

• Ramelteon 8 mg is the preferred non-controlled option, taken 30 minutes before bedtime as a melatonin-receptor agonist with minimal abuse potential and favorable safety profile. 1, 2
• Ramelteon shows efficacy for reducing sleep latency but has significantly smaller effect sizes compared to benzodiazepine-receptor agonists. 1, 2
• This agent is particularly appropriate for patients with substance use history or concerns about dependence. 3

For Sleep-Maintenance Insomnia (Frequent Awakenings, Early Morning Awakening)

• Low-dose doxepin 3–6 mg is recommended specifically for sleep maintenance, increasing total sleep time by 26–32 minutes and reducing wake after sleep onset by 22–23 minutes compared to placebo. 2

• Start at 3 mg nightly taken 30 minutes before bedtime; if insufficient response after 1–2 weeks, titrate to 6 mg. 2

• Never prescribe the 10 mg capsule for insomnia—it provides no additional sleep benefit beyond 6 mg and increases anticholinergic side effects. 2

• At the 3–6 mg range, doxepin selectively blocks histamine H₁ receptors with minimal anticholinergic effects, though dry mouth occurs in approximately one in eight patients. 2, 3

• Suvorexant 10–20 mg (orexin receptor antagonist) is an alternative for sleep maintenance with superior tolerability compared to older hypnotics and lower abuse potential than GABAergic agents. 1, 2

• Initial dose is 10 mg (or 15 mg in adults ≥65 years), taken within 30 minutes of bedtime with at least 7 hours of sleep opportunity; titrate to 20 mg if needed after 1–2 weeks. 2

• Suvorexant preserves natural sleep architecture and exhibits fewer cognitive side effects than benzodiazepines or Z-drugs. 2, 3

For Both Sleep-Onset and Sleep-Maintenance Problems

• No non-controlled medication has strong evidence for treating both domains simultaneously. 1
• Consider combining ramelteon for sleep onset with behavioral strategies, or use suvorexant which has modest effects on both domains. 2, 3

Medications Explicitly NOT Recommended (Negative Guidelines)

Trazodone

• The American Academy of Sleep Medicine recommends against using trazodone for either sleep-onset or sleep-maintenance insomnia because harms outweigh benefits despite frequent off-label prescribing. 1, 2
• Trazodone carries significant risks including orthostatic hypotension, cardiac arrhythmias, and priapism, with insufficient efficacy data to justify these risks. 4

Diphenhydramine

• Explicitly not recommended due to anticholinergic effects that are especially problematic in older adults, including cognitive impairment, urinary retention, and increased fall risk. 1, 2
• The American Academy of Sleep Medicine issued a negative recommendation against diphenhydramine for both sleep-onset and sleep-maintenance insomnia. 1

Melatonin (Over-the-Counter)

• Not recommended for adult insomnia—the American Academy of Sleep Medicine found insufficient evidence of efficacy for either sleep-onset or sleep-maintenance outcomes. 1, 2
• The American College of Physicians classified evidence for melatonin agonists as low-strength, reinforcing the recommendation to avoid over-the-counter melatonin. 3
• Melatonin only slightly improves sleep onset and duration, with variable product quality and efficacy. 4

Other Agents to Avoid

• Tiagabine, tryptophan, and valerian all carry negative recommendations due to lack of efficacy or unfavorable risk-benefit profiles. 1, 2
• Magnesium has insufficient evidence to support use for insomnia and should not be recommended based on social media popularity or patient demand. 3

Critical Safety Considerations

Observational Harms Data

• Observational studies link hypnotic use (including non-benzodiazepine agents) to increased risk of dementia (2.34-fold increased risk for tricyclics), fractures, and major injuries, particularly in older adults. 2, 3
• The FDA has reported cognitive and behavioral changes, including impaired driving, associated with various sleep medications. 2

Special Population Dosing

• Women and older adults require dose reductions for most sleep-aid pharmacotherapies due to altered metabolism and higher adverse-event risk. 2
• Elderly patients (≥65 years) should start doxepin at 3 mg with close monitoring for confusion, falls, and anticholinergic toxicity. 2
• For suvorexant, use 15 mg maximum in adults ≥65 years rather than the standard 20 mg. 2

Contraindications for Doxepin

• Screen for glaucoma, urinary retention, and hypersensitivity to tricyclic antidepressants before prescribing doxepin, as these are absolute contraindications. 2

Treatment Duration and Monitoring

• Acute treatment of 4–12 weeks is supported by efficacy data for most agents; reassess if continuing beyond this window. 2, 3
• Doxepin does not require tapering when discontinued, unlike benzodiazepines or Z-drugs, simplifying deprescribing. 2
• Document failure of cognitive-behavioral therapy for insomnia (CBT-I) or its unavailability before initiating pharmacotherapy. 2

Common Clinical Pitfalls to Avoid

• Do not combine multiple sedative-hypnotics without clear indication—this multiplies safety risks without evidence of added benefit. 3
• Do not prescribe doxepin 10 mg for insomnia—the 10 mg capsule is intended for depression treatment and provides no extra sleep efficacy while increasing adverse effects. 2
• Do not continue ineffective therapy beyond 2–4 weeks without reassessment, as this increases dependence risk without additional benefit. 3
• Do not use amitriptyline—it is not FDA-approved for insomnia and carries a 2.34-fold increased dementia risk with higher rates of falls and fractures in older adults. 2
• Avoid routine benzodiazepine use due to high risks of dependence, cognitive decline, falls, and fractures, especially in older adults. 3, 5

Algorithm for Non-Controlled Medication Selection

1. Confirm chronic insomnia diagnosis and document failure of non-pharmacologic interventions. 2

2. Identify primary sleep complaint:

   • Sleep-onset difficulty only → Ramelteon 8 mg 2, 3
   • Sleep-maintenance difficulty only → Doxepin 3–6 mg OR Suvorexant 10–20 mg 2, 3
   • Both onset and maintenance → Suvorexant 10–20 mg (modest effects on both) 2, 3

3. Consider patient-specific factors:

   • History of substance use disorder → Prioritize ramelteon, doxepin, or suvorexant (avoid all controlled substances) 3
   • Age ≥65 years → Use lower doses; favor suvorexant 15 mg, doxepin 3 mg, or ramelteon 8 mg 2, 5
   • Cognitive impairment concerns → Select suvorexant or ramelteon over GABAergic agents 3
   • Anticholinergic sensitivity → Avoid doxepin; use suvorexant or ramelteon 2

4. Initiate at lowest effective dose and titrate only if insufficient response after 1–2 weeks. 2

5. Plan for 4–12 week acute treatment course with scheduled reassessment. 2, 3